DOWN SYNDROME REGRESSION DISORDER

Jonathan D. Santoro, MD
Director of Neuroimmunology and Demyelinating Disorders
Children’s Hospital Los Angeles & Keck School of Medicine of USC
What is Regression?

- Regression is a term for the **loss or previously acquired developmental skills** in an individual.

- This can be activities (toileting, dressing oneself, or eating independently), language (loss of words, loss of ability to community, changes or regression in word structure), motor function (inability to walk, climb or run as previously able), or social interaction.

- **Regression can be caused by many things.**
Is Regression Common?

- It is difficult to know as it is very likely that persons experiencing symptoms of regression can go undiagnosed in the community setting.
- Frequent alternative diagnoses are “late onset autism”, “early onset Alzheimer’s disease” and other primary psychiatric diagnoses like depression.

- Currently, we think regression is relatively rare, effecting <5% of all individuals with Down syndrome who are older than 10 years old and younger than 30 years old.
What Causes Regression?

- At this time, it appears that **there may be several causes of regression** in persons with Down syndrome.
  - Traditionally, this condition was thought to be psychiatric although we are learning there are a variety of causes.

- As regression is a description of the symptom (what is happening), this label does not always describe the cause.

- **Timing matters!**
  - Acute (sudden) or sub-acute (few weeks) from the start of symptoms may be different then chronic or slowly changing symptoms
Symptoms of Regression (Part I)

Mental Status Changes or Behavioral Dysregulation
- Confusion, disorientation
- Inappropriate laughter and laughing at things that are not present
- Being “off in your own world” for extended periods of time
- Increased or decreased eating with corresponding weight loss/gain

Cognitive Decline
- Apathy or lack of interest in things going on around them
- Avolition or limited interest in initiating activity
- Memory impairment or difficulty with recall

Insomnia or Circadian Rhythm Dysregulation
- Inability to sleep or sleeping >16 hours per day
- Reversal of sleep patterns (sleeping all day, up all night)
Symptoms of Regression (Part II)

**Developmental Regression**
- Social withdrawal
- Loss of previously acquired developmental milestones
- Inability to perform activities of daily living (e.g., toileting, brushing teeth, eating, dressing self)
- Decreased eye contact
- Rigidity around routine changes (extreme inflexibility)
- Stereotypy or repetitive motor behaviors

**New Focal Neurologic Deficits**

**Movement Disorder (excluding tics)**
- Catatonia or muscle stiffness
- Bradykinesia (slow movements) or freezing behavior (stuck in place)
- Gait disturbance or inability to walk normally
Symptoms of Regression (Part III)

**Language Deficits**
- Expressive and/or receptive aphasia (e.g., decreased speaking and/or decreased ability to understand speech)
- Whispered speech
- Neologisms (using new or garbled words)
- Global aphasia (mutism)

**Psychiatric Symptoms**
- Anxiety
- Delusions or hallucinations
- Derealization or depersonalization (belief that you are in a dream or not in reality)
- Obsessive compulsive tendencies (new)
- Aggression/agitation
Our Current Understanding...

- Persons with Down syndrome are at risk for a variety of psychiatric, neurologic, and immunologic disorders.

- Regression may be caused by one, multiple, or all of these causes and each case is very unique.

- We advised a broad work up prior to the diagnosis of regression to make sure there is not another medical explanation for the symptoms.

- At present, regression is a “diagnosis of exclusion”
How to Make the Diagnosis?

There is not one specific test used to diagnose regression.

Rather, we use multiple tests to rule out other medical explanations for this condition.

**Blood Work:** helps rule out metabolic, gastrointestinal, nutritional, infectious, and some inflammatory disorders that can mimic the symptoms of regression.

**MRI:** helps determine if there is a structural cause (brain anatomy) that can explain regression or determine if there is stroke, inflammation or other causes to symptoms.

**EEG:** is used to determine if seizures are a potential cause to symptoms and also evaluate if there is slower than expected brain activity.

**Lumbar Puncture (Spinal Tap):** helps determine if there is inflammation or infection in the brain
Beyond Diagnosis…

- Arriving at the most likely reason for regression in a person with Down syndrome is very important as the therapies that can be offered vary widely on what the explanation is.

- We encourage discussion with other families about regression but please be aware that no case of regression is exactly like the next.

- If a therapy is not working or providing only partial or temporary results, it is OK to ask your doctor why and if additional testing should be done.

- We as a medical community are still learning the best ways to test and treat persons with Down syndrome and regression and an open dialogue between you and your doctor is the best way to optimize care.
Is there a treatment?

- Right now, **there is no one singular treatment for persons with regression**. However, once a source (or reason) is found for regression, your doctors can work together to provide the best treatment options.

- Given the overlap between psychiatric and neurologic disease, working with a multi-disciplinary team of doctors with expertise in regression is very important!

- Many different treatments have been used, all with some aspect of success although prediction of who will respond to what therapy best is very difficult.
Down Syndrome Regression Disorder

- Antidepressants
- Antipsychotics
- Benzodiazepines
- Cholinergic Agents
- Electroconvulsive Therapy
- Immunotherapy
QUESTIONS?

dsresearch@chla.usc.edu | 323-361-2471
Clinical Trial for Mechanistic Investigation of Therapies for Down syndrome Regression Disorder

October 6th, 2022
Joaquin M. Espinosa, PhD
Clinical trial for mechanistic investigation of therapies for Down syndrome Regression Disorder

A collaboration between the Crnic Institute, Children's Hospital Colorado, and Children’s Hospital Los Angeles.

Principal Investigators:

Santoro  
Sannar  
Espinosa

Co-Investigators:

Rachubisnki  
Patel  
Kammeyer  
Galbraith

Consultants:

Sanders  
Tartaglia  
Charoensook

Funded by:
Clinical trial for mechanistic investigation of therapies for Down syndrome Regression Disorder

Three goals:

1. To define the relative **safety** profile of Lorazepam, IVIG, and Tofacitinib in DSRD.

2. To compare the **efficacy** of Lorazepam, IVIG, and Tofacitinib in DSRD.

3. To investigate potential **mechanisms** underlying DSRD and its response to therapies.
A Phase II, three-arm, open-label, research intensive trial

Labatory Studies
- Cell or animal studies test to see if the new treatment will be safe and will work on people.

Phase I
- Studies the safety of medication and treatment on people.

Phase II
- Studies the safety and effectiveness on people.

Phase III
- Studies the safety, effectiveness and dosing on people.

Phase IV
- Studies the long-term effectiveness and compares new treatment to standard treatment on people.

Drug approved for testing in humans

Drug approved for treatment of a medical condition

All three medicines studied in this trial are already FDA-approved for treatment of other medical conditions.
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

All three medicines studied in this trial are already FDA-approved for other medical conditions.

The power of ‘drug repurposing’: this study benefits from extensive available data for all three drugs.

Open label: participants will know which medicine they are taking.

No placebo arm.
A Phase II, three-arm, open-label, research intensive trial

Lorazepam  
Brand name: Ativan  
Benzodiazepine

IVIG  
Brand name: Gammagard  
Intravenous Immune Globulin

Tofacitinib  
Brand name: Xeljanz  
JAK inhibitor

All three medicines studied in this trial are already FDA-approved for other medical conditions:

Lorazepam is a benzodiazepine approved for anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.

Lorazepam modulates ‘brain chemistry’ through binding to ‘GABA receptors’ in neurons
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

All three medicines studied in this trial are already FDA-approved for other medical conditions:

**IVIG** is approved for primary humoral immunodeficiency, multifocal motor neuropathy, B cell chronic lymphocytic leukemia, immune thrombocytopenic purpura, Kawasaki syndrome, and chronic inflammatory demyelinating polyneuropathy.

**IVIG** modulates the immune system by ‘flooding it’ with immunoglobulins, a.k.a. antibodies.
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

All three medicines studied in this trial are already FDA-approved for other medical conditions:

Tofacitinib is approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.

Tofacitinib lowers inflammation by inhibiting a class of enzymes known as Janus kinases (JAKs)
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

Potential side effects of Lorazepam: sedation, dizziness, weakness, unsteadiness, physical and psychological dependence, fatigue, drowsiness, amnesia, memory impairment, confusion, disorientation, depression, others.

Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

All three medicines have well characterized safety profiles (in the general population):
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

All three medicines have well characterized safety profiles (in the general population):

Potential side effects of IVIG: Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting, or dizziness, bad headache with nausea, vomiting, stiff neck, fever, sensitivity to light, others.

Learn more at: https://www.fda.gov/media/70812/download
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

All three medicines have well characterized safety profiles (in the general population):

Potential side effects of Tofacitinib: increased risk of infections, nasopharyngitis, diarrhea, headache, elevated cholesterol levels, increased risk of cardiovascular events, thrombosis and malignancies relative to TNF-blockers, others.

Learn more:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf
A Phase II, three-arm, open-label, research intensive trial

Lorazepam  
Brand name: Ativan  
Benzodiazepine

IVIG  
Brand name: Gammagard  
Intravenous Immune Globulin

Tofacitinib  
Brand name: Xeljanz  
JAK inhibitor

All three medicines have benefited some individuals affected by DSRD!  
Study doctors have safely administered these medicines to those affected by DSRD!
A Phase II, three-arm, open-label, research intensive trial

Lorazepam
Brand name: Ativan
Benzodiazepine

IVIG
Brand name: Gammagard
Intravenous Immune Globulin

Tofacitinib
Brand name: Xeljanz
JAK inhibitor

What causes DSRD?
Who will benefit the most from which medicine?
A lot of research will be needed to answer these questions
Summary of Study Design

- Only individuals with Down syndrome Regression Disorder
- Ages 8-30
- 12 weeks (3 months) of treatment with one medicine
- 60 participants total, 20 on each medicine
- Two sites, Denver and Los Angeles, 30 participants each

Anschutz Medical Campus

Children’s Hospital Los Angeles
Summary of Study Design

• Primary endpoint: safety!

• Secondary and tertiary endpoints: improvements in various symptoms of DSRD.

- Global Neurological Health
- Movement & Visuomotor Function
- Catatonia
- Executive Function & Cognitive Ability
- Language
- Quality of Life
- Sleep
- Behavior and Social Interaction
# Summary of Study Design

## Schedule of activities

<table>
<thead>
<tr>
<th></th>
<th>Screening Visit 1 (-4 weeks)</th>
<th>Baseline Visit 2 (0 weeks)</th>
<th>Visit 3 (2 weeks)</th>
<th>Visit 4 (4 weeks)</th>
<th>Visit 5 (8 weeks)</th>
<th>Endpoint Visit 6 (12 weeks)</th>
<th>Follow-up Visit 7 (14 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening labs</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety monitoring</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Psychiatric exam</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>DSRD diagnostic work-up</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Pharmacy visit</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological exam</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Endpoint measurements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>

A lot of important work!
Why compare these three medicines?

• A subset of DSRD cases are associated with signs of immune dysregulation affecting the central nervous system (CNS).

• Is DSRD an autoimmune condition, akin to autoimmune encephalitis?

• What is the value of immune therapies relative to psychiatric medicines?
Why compare these three medicines?

Who would benefit the most from which medicine?

What are the diagnostic characteristics that could predict a good response?

Are there ‘biomarkers’ in the blood or cerebrospinal fluid that could match each participant to their best therapeutic option?

Developing a personalized medicine approach for the treatment of DSRD
A research-intensive clinical trial

• Blood samples and cerebrospinal fluid samples will be collected for deep analysis using cutting-edge technologies.

• Each participant will undergo significant testing to monitor for potential improvements in diverse areas of brain function.

• A multidisciplinary team with expertise in psychiatry, neurology, psychology, immunology, genetics, and molecular biology will analyze the data.
Important facts

• Recruitment will start sometime in 2023 after obtaining all required regulatory approvals and oversight (in progress).

• An interim analysis will be completed after recruitment of the first ~20 participants, before scaling up to ~60 participants.

• Travel and lodging assistance will be provided.

• Participation in the trial will not prevent participants from receiving other medicines (including those tested in the trial) after the trial.

• Stay tuned!

dsresearch@cuanschutz.edu  dsresearch@chla.usc.edu
Thanks to GLOBAL, today is a new age in Down syndrome research, with new NIH funding opportunities, new cohort studies, new clinical trials, and new big data science efforts. The future is bright!